drugset / Trial / NCT04678791

Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma

NCT04678791

Unknown 286 enrolled Peking University Third Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate the efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of local advanced cervical squamous cell carcinoma.

Timeline

Start
2020-12
Primary completion
2024-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimotuzumab Monoclonal antibody 400 mg Intravenous
Background Cisplatin Other / unclassified 40 mg/m2